Why We Should Use IVUS in Complex Coronary Lesions

Courtesy of Dr. Carlos Fava.

IVUS in Complex Coronary LesionsDrug eluting stents (DES) have shown benefits in terms of restenosis vs. conventional bare metal stents (BMS). Many of the advantages of DES depend on correct implantation, especially in complex lesions.

 

In complex lesions, the use of intravascular ultrasound (IVUS) provides important information on lesion length, vessel diameter, calcification degree, plaque morphology, etc. We are well aware of the value of IVUS, yet it remains underused, both in developed and underdeveloped countries.

 

This meta-analyzis included 8 randomized studies of patients with complex lesions (long or requiring ≥4 stents, small vessels, bifurcations or chronic total occlusions) with at least one year follow up.

 

In all, 3,276 patients were analyzed; 1,635 were guided with IVUS and 1,671 with angiography. Populations were homogeneous. Follow up was at 1.4 ± 5 years.

 

Combined adverse events rate was reduced 36% with the use of IVUS (6.5% vs. 10.5%; p=0.0001), the same as lesion revascularization rate (5.5% vs. 9.2%; p=0.007) and there was a tendency to less cardiovascular death. There were no differences in events such as stent thrombosis and all cause death.

 

IVUS guided DES stenting showed significant benefits in combined events reduction in diabetic patients with long lesions undergoing acute coronary syndrome.

 

 

Conclusion

This meta-analyzis shows a significant reduction of combined adverse events and revascularization with IVUS guided DES implantation in coronary complex lesions.

 

Editorial Comment

These data show that the use of IVUS in coronary complex lesions reduces MACE at the expense of reintervention, especially in high risk populations. With this information we should start to use is more frequently.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

Original Title: Intravascular ultrasound-guided vs angiography-guided drug-eluting stent implantation in complex coronary lesions: Meta-analysis of randomized trial.

Reference: Chirag Bavishi et al, Am Heart J 2017;185:26-34.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....